This is one of a series of BMJ summaries of new guidelines based on the best available evidence; they highlight important recommendations for clinical practice, especially where uncertainty or controversy exists.
Venous thromboembolic diseases range from asymptomatic deep venous thrombosis (DVT) to fatal pulmonary embolism. Non-fatal venous thromboembolic diseases may also cause serious long term conditions such as post-thrombotic syndrome or chronic thromboembolic pulmonary hypertension. In the United Kingdom, pathways to diagnosis and to decisions on long term treatment or further investigation for thrombophilia and cancer vary, so guidance is needed in these areas. This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of confirmed or suspected venous thromboembolic diseases in adults (excluding pregnant women).
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Recommendations
NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Diagnostic investigations for deep venous thrombosis
• If a patient presents with signs or symptoms of DVT, conduct an assessment of his or her general medical history and a physical examination to exclude other causes.
[Based on the experience and opinion of the Guideline Development Group (GDG)]
• For patients in whom DVT is suspected and who score ≥2 ("DVT likely") on the Wells scoring system ( 
Drug interventions for confirmed deep venous thrombosis or pulmonary embolism
• Offer a choice of low molecular weight heparin or fondaparinux, taking into account comorbidities, contraindications, and drug costs, with the following exceptions: -For patients with severe renal impairment or established renal failure (estimated glomerular filtration rate <30 ml/min/1.73 m 2 ), offer unfractionated heparin with dose adjustments based on the activated partial thromboplastin time, or low molecular weight heparin with dose adjustments based on an anti-factor Xa assay -For patients with an increased risk of bleeding, consider unfractionated heparin -For patients with pulmonary embolism and haemodynamic instability, offer unfractionated heparin and consider thrombolysis.
Start the low molecular weight heparin, fondaparinux, or unfractionated heparin as soon as possible and continue it for five days or until the international normalised ratio (adjusted by a vitamin K antagonist-see the next recommendation) is ≥2 for at least 24 hours, whichever is longer. [Based on very low to moderate quality evidence from randomised controlled trials and on cost effectiveness studies with potentially serious limitations and partial applicability for the type of agent; the other aspects were based on the GDG's experience and opinion and on information from marketing authorisation of products]
• Offer low molecular weight heparin to patients with active cancer and confirmed proximal DVT or pulmonary embolism, and continue the heparin for six months. 
Investigations for thrombophilia
• Do not offer thrombophilia testing to patients who are continuing anticoagulation treatment, or to those who have had "provoked" DVT or pulmonary embolism (that is, patients who in the past three months have had a transient major clinical risk factor for venous thromboembolic disease)-for example, surgery, trauma, prolonged immobility (confined to bed, unable to walk unaided, or likely to spend a substantial proportion of the day in bed or in a chair), pregnancy, or puerperium-or patients who are having hormonal therapy (oral contraception or hormone replacement therapy)).
• Consider testing for antiphospholipid antibodies in patients who have had unprovoked DVT or pulmonary embolism if stopping anticoagulation treatment is planned.
• Consider testing for hereditary thrombophilia in patients who have had unprovoked DVT or pulmonary embolism and who have a first degree relative who has had DVT or pulmonary embolism if stopping anticoagulation treatment is planned.
• Do not routinely offer thrombophilia testing to first degree relatives of people with a history of DVT or pulmonary embolism and thrombophilia.
[All the above recommendations are based on the GDG's experience and opinion]
Overcoming barriers
Although it is important that the recommended key diagnostic tests are available when required, the Guideline Development Group recognises the potential difficulties and delays in accessing computed tomography pulmonary angiography, ventilation and perfusion scanning, or ultrasonography, especially at weekends and outside normal working hours. It has therefore recommended interim anticoagulation and time limits for accessing these tests. The guideline also recommends catheter directed thrombolysis for some patients; relatively few such interventions are currently undertaken in the NHS, and there may be some resource implications for centres that do not currently offer this treatment, requiring changes to facilities or local referral arrangements for appropriate patients.
Patients with cancer should be offered subcutaneous low molecular weight heparin instead of oral vitamin K antagonist, but patients who cannot self inject may need a carer or district nurse to administer these daily injections. Whenever possible, patients or carers should be trained in injection technique, to limit the numbers needing nurse delivered injections, which would potentially increase costs. The recommendation to assess the risks and benefits of continuing treatment with a vitamin K antagonist at three months may also have clinical, resource, and/or economic implications. Factors associated with risk of recurrence after an unprovoked initial venous thromboembolic event are debated; factors include male sex, 4-6 post-thrombotic syndrome, 6 7 obesity, and a raised D dimer after stopping anticoagulation. 8 9 As there are no simple rules of thumb or validated tools to reliably predict these risks, the decisions will often have to be taken in a secondary care setting. Contributors: L-YC, EF, and SH wrote the first draft, and all authors were involved in writing further drafts and reviewed and approved the final version for publication. GS is the guarantor.
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Further information on the guidance
Methods
The Guideline Development Group followed the standard NICE methods in the development of this guideline (www.nice.org.uk/aboutnice/ howwework/developingniceclinicalguidelines/developing_nice_clinical_guidelines.jsp). 10 The group developed clinical questions, collected and appraised clinical evidence, and evaluated the cost effectiveness of proposed interventions through literature review and original economic modelling. The draft guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; the group took all comments into consideration when producing the final version of the guideline. Quality ratings of the evidence were based on GRADE methodology (www.gradeworking group.org). These relate to the quality of the available evidence for assessed outcomes rather than the quality of the clinical study.
The GDG comprised two vascular surgeons, two patient representatives, two haematologists, a general practitioner, an oncologist, an acute medical physician, a pharmacist, a nurse, a radiologist, a respiratory consultant, and a geriatrician.
Future research
• What is the clinical and cost effectiveness of a whole-leg ultrasound scan compared with a proximal leg vein ultrasound scan in the diagnosis of acute deep venous thrombosis?
• What is the clinical and cost effectiveness of long term oral anticoagulation treatment in specific subgroups of patients with first unprovoked venous thromboembolic disease?
• In patients with venous thromboembolic disease and active cancer who have had six months of anticoagulation treatment with low molecular weight heparin, what is the clinical benefit (in terms of recurrence rates of venous thromboembolic disease, all cause mortality, and major bleeding) and cost effectiveness of continued anticoagulation treatment with low molecular weight heparin versus a vitamin K antagonist?
• What is the clinical and cost effectiveness of clot removal using catheter directed drug thrombolysis or pharmacomechanical thrombolysis compared with standard anticoagulation therapy for the treatment of acute proximal deep venous thrombosis?
• What is the clinical and cost effectiveness of systemic drug thrombolysis compared with standard initial anticoagulation treatment in patients with confirmed pulmonary embolism and haemodynamic stability who present with right ventricular dysfunction? Tables   Table 1| Wells 
